Temple University Hospital and Fox Chase Researchers Investigate Survival Outcomes Following Adjuvant Treatment in Clinical T2N0 Rectal Cancer Patients
PHILADELPHIA (May 20, 2024) — Adjuvant therapy in patients with clinical T2N0 rectal cancer may currently be underutilized, according to the findings of a study from researchers at Temple University Hospital and Fox Chase Cancer Center. The research was presented yesterday at Digestive Disease Week (DDW).